Erina E V, Basishvili N Z
Kardiologiia. 1978 Mar;18(3):28-35.
The results of treatment of over 300 patients suffering from hypertensive disease with beta-blocking agents Obsidan and Visken are analysed and the place of these agents among other hypotensive drugs is discussed. The therapeutic effect was most evident in patients with the early stages of the disease and hyperkinetic type of circulation. The daily doses were from 60 to 240 mg. The hemodynamic shifts were displayed by a decrease in the cardiac output and rate of cardiac contractions and reflex, ususlly moderate, increase in general peripheral resistance, as a result the arterial pressure decreased gradually. In 1 to 6 months general peripheral resistance diminished in half of the patients, evidently due to the gradual adaptation of the vascular tone to the chronic reduction of the cardiac output. Treatment with beta-blocking agents led to non-uniform changes in regional hemodynamics: the tone of the cerebral arteries significantly reduced, the tone of the arteries of the lower extremities had a tendency to increase. This gives rise to the conclusion that alpha-adrenergic receptors predominate in the vessels of the lower extremities. In the treatment of patients with high and stable hypertension, it is advisable to combine beta-blocking agents with saluretics, vasodilators, hemiton, and other hypotensive drugs.
分析了使用β受体阻滞剂奥昔坦和吲哚洛尔治疗300多名高血压病患者的结果，并讨论了这些药物在其他降压药物中的地位。治疗效果在疾病早期和高动力循环型患者中最为明显。每日剂量为60至240毫克。血流动力学变化表现为心输出量和心脏收缩率降低，以及通常为中度的反射性全身外周阻力增加，结果动脉压逐渐下降。在1至6个月内，一半患者的全身外周阻力降低，这显然是由于血管张力逐渐适应心输出量的慢性降低。使用β受体阻滞剂治疗导致区域血流动力学发生不均匀变化：脑动脉张力显著降低，下肢动脉张力有增加趋势。由此得出结论，下肢血管中α肾上腺素能受体占主导。在治疗高血压高且稳定的患者时，建议将β受体阻滞剂与利尿剂、血管扩张剂、海米通和其他降压药物联合使用。
